Cormorant reports 5.38% stake in BioAge Labs
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of BioAge Labs, Inc. common stock on an amended Schedule 13G. They collectively report beneficial ownership of 2,390,605 shares of common stock, representing 5.38% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of BioAge Labs, Inc. common stock on an amended Schedule 13G. They collectively report beneficial ownership of 2,390,605 shares of common stock, representing 5.38% of the class.
All 2,390,605 shares are reported with shared voting power and shared dispositive power, with no sole voting or dispositive power. The percentage is calculated using 44,452,734 shares of BioAge Labs common stock outstanding as of May 1, 2026, as disclosed in the company’s Quarterly Report for the period ended March 31, 2026.
Key Figures
Key Terms
beneficial owner regulatory
Percent of class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in BioAge Labs (BIOA) does Cormorant Asset Management report?
How was the 5.38% ownership of BIOA calculated in this filing?
Who are the reporting persons in this BIOA Schedule 13G/A filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.